1
Home
Companies

Kadimastem

Kadimastem
Leadership team

Dr. Michal Harel Izrael (VP of R&D for ALS and Neurodegenerative Diseases)

Mr. Asaf Shiloni (Chief Exec. Officer)

Dr. Arik Hasson Ph.D. (Exec. VP of Bus. Devel.)

Products/ Services
Biotechnology, Therapeutics
Number of Employees
0 - 50
Headquarters
Ness Ziona, HaMerkaz, Israel
Established
2009
Traded as
TLV:KDST
Social Media
URL
https://www.kadimastem.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was founded in 2008 and is based in Ness Ziona, Israel.
History

Kadimastem was founded in 2004 by a team of scientists with a vision to make a difference in the lives of people suffering from serious medical conditions. Over the years, Kadimastem has developed its technology platform, expanded its product portfolio and partnerships, attracted a world-class team of experts and investors, and produced remarkable clinical results in the therapeutic areas of stem cell technology, autoimmune diseases, and kidney diseases.

Mission
Our mission is to develop life-changing treatments for patients with serious medical conditions and provide hope to the millions of people affected by the global health crisis.
Vision
Our vision is to become the world’s leading biotechnology company in developing and delivering life-changing treatments for serious medical conditions.
Key Team

Prof. Michel Revel M.D., Ph.D. (Co-Founder, Chief Scientist, Head of the Scientific Advisory Board & Director)

Mr. Yossi Ben-Yossef (Honorary Pres & Strategic Consultant)

Recognition and Awards
Kadimastem has received numerous awards, including the 2018 Reimagining Medicine Award from the American Association for the Advancement of Science and the 2019 World Technology Award for Therapeutics from the World Technology Network. We have also been published in multiple peer-reviewed journals and have been featured on various media outlets such as TED, BBC World News, and The Wall Street Journal.
References

https://in.investing.com/equities/kadimastem

https://finance.yahoo.com/quote/KMSTF/profile?p=KMSTF

https://www.crunchbase.com/organization/kadimastem

https://www.kadimastem.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Kadimastem
Leadership team

Dr. Michal Harel Izrael (VP of R&D for ALS and Neurodegenerative Diseases)

Mr. Asaf Shiloni (Chief Exec. Officer)

Dr. Arik Hasson Ph.D. (Exec. VP of Bus. Devel.)

Products/ Services
Biotechnology, Therapeutics
Number of Employees
0 - 50
Headquarters
Ness Ziona, HaMerkaz, Israel
Established
2009
Traded as
TLV:KDST
Social Media
URL
https://www.kadimastem.com